{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:55:22Z","timestamp":1787014522942,"version":"build-2736575974"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1834,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1111\/j.1365-2710.2010.01184.x","type":"journal-article","created":{"date-parts":[[2010,8,29]],"date-time":"2010-08-29T13:13:02Z","timestamp":1283087582000},"page":"419-425","source":"Crossref","is-referenced-by-count":13,"title":["Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition"],"prefix":"10.1155","volume":"36","author":[{"given":"M.","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. W. L.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,24]]},"reference":[{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amjmed.2003.10.033","article-title":"Current overview of statin-induced myopathy","volume":"116","author":"Rosenson","year":"2004","journal-title":"American Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy - a genomewide study","volume":"359","author":"The SEARCH CollaborativeGroup","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB4|cit4","unstructured":"The Food and Drug Administration 2008 Information on simvastatin\/ amiodarone http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm095009.htm"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1161\/01.ATV.18.10.1600","article-title":"Mutations in the low-density lipoprotein receptor gene in Chinese familial hypercholesterolemia patients","volume":"18","author":"Mak","year":"1998","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","article-title":"New insights into the pharmacodynamic and pharmacokinetic properties of statins","volume":"84","author":"Corsini","year":"1999","journal-title":"Pharmacology and Therapeutics"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1592\/phco.26.11.1601","article-title":"Role of P-glycoprotein in statin drug interactions","volume":"26","author":"Holtzman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1067\/mcp.2000.104609","article-title":"The interaction of diltiazem with simvastatin","volume":"67","author":"Mousa","year":"2000","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/sj.clpt.6100098","article-title":"Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics","volume":"81","author":"Becquemont","year":"2007","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0002-9149(99)00442-7","article-title":"Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin","volume":"84","author":"Gruer","year":"1999","journal-title":"American Journal of Cardiology"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.lfs.2004.06.022","article-title":"Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension","volume":"76","author":"Watanabe","year":"2004","journal-title":"Life Sciences"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB12|cit12","doi-asserted-by":"crossref","DOI":"10.1177\/0091270009358082","article-title":"Effects of concomitant therapy with diltiazem on the lipid responses to simvastatin in Chinese subjects","author":"You","year":"2010","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00002018-200831070-00004","article-title":"Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors","volume":"31","author":"Molden","year":"2008","journal-title":"Drug Safety"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00002018-200629110-00005","article-title":"Risk factors for rhabdomyolysis with simvastatin and atorvastatin","volume":"29","author":"Ronaldson","year":"2006","journal-title":"Drug Safety"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB15|cit15","first-page":"339","article-title":"Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis","volume":"94","author":"Kanathur","year":"2001","journal-title":"Tennesse Med"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000046056","article-title":"Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem","volume":"89","author":"Peces","year":"2001","journal-title":"Nephron"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1345\/aph.1A481","article-title":"Rhabdomyolysis with concurrent atorvastatin and diltiazem","volume":"36","author":"Lewin","year":"2002","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"W31","DOI":"10.7326\/0003-4819-140-8-200404200-00037-w1","article-title":"Potentially fatal interaction between diltiazem and statins","volume":"140","author":"Gladding","year":"2004","journal-title":"Annals of Internal Medicine"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB19|cit19","first-page":"264","article-title":"Multiple drug interactions in a renal transplant patient leading to simvastatin-induced rhabdomyolysis: a case report","volume":"10","author":"Rifkin","year":"2008","journal-title":"Medscape Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1592\/phco.29.3.352","article-title":"Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction","volume":"29","author":"DiGregorio","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB21|cit21","first-page":"176e","article-title":"Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction - what about the diltiazem?","volume":"29","author":"Hu","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1111\/j.1365-2710.2010.01184.x-BIB24|cit24","doi-asserted-by":"crossref","DOI":"10.1038\/clpt.2009.232","article-title":"ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin","author":"Tomlinson","year":"2010","journal-title":"Clinical Pharmacology and Therapeutics"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2010.01184.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2010.01184.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T13:03:50Z","timestamp":1671800630000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2010.01184.x"}},"subtitle":["<i>Simvastatin-induced myopathy<\/i>"],"short-title":[],"issued":{"date-parts":[[2010,8,24]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2010.01184.x","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8,24]]}}}